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Traditionally, the curative treatment of liver cancer has involved either surgical resection, liver transplantation \[[@B1]\], or local ablation, whereas transarterial tumor embolization has been used for palliative treatment \[[@B2]\]. Drug treatment for the more advanced stages of liver cancer has been attempted in the form of conventional chemotherapy in numerous usually uncontrolled clinical trials over the past 50 years \[[@B3]\], but neither doxorubicin nor any other of the traditionally used chemotherapy agents has given a survival advantage in a controlled clinical trial. In 2008, sorafenib was shown to improve overall survival in advanced-stage hepatocellular carcinoma (HCC) in a large prospective randomized controlled trial \[[@B4]\], and this improvement was confirmed in a second trial with similar design in an Asian population \[[@B5]\]. These two positive phase-III trials consequently led to the introduction of sorafenib as the standard of care for advanced-stage liver cancer. In the current European Association for the Study of the Liver (EASL) clinical practice guidelines on the management of liver cancer, the curative treatment options (resection, liver transplantation, and percutaneous ablation) are reserved for very early and early stage HCC patients with good performance status and reasonable liver function, whereas intermediate-stage tumors are treated by transarterial chemoembolization \[[@B6], [@B7], [@B8]\]. For advanced-stage patients with portal invasion, extrahepatic spread, or reduced performance status, sorafenib is the standard of care \[[@B7], [@B9]\].

First-Line Treatment for Advanced-Stage HCC {#sec1_2}
===========================================

Sorafenib is a raf-, vascular endothelial growth factor (VEGF) receptor-, platelet-derived growth factor (PDGF) receptor-blocking multikinase tyrosine kinase inhibitor (TKI) \[[@B10]\]. After the initial publication of quite promising phase-II results for sorafenib in advanced-stage liver cancer in 2006 \[[@B11]\], the results of two phase-III trials were eagerly awaited. In 2008, the SHARP trial was finally published and showed a significant overall survival (OS) advantage in patients treated with sorafenib versus patients treated with placebo \[10.7 versus 7.9 months, hazard ratio (HR) 0.69, p\<0.001\]. The trial was conducted in a mostly European patient cohort (including some US patients) with well-preserved liver function (Child A) and good performance status (PS0-2) but with either large intrahepatic tumors, tumors with vascular invasion, or with extrahepatic spread of HCC \[[@B4]\]. A little later, very similar data from the phase III Asia-Pacific study also reported a significant survival benefit with sorafenib versus placebo (HR 0.68, p=0.014) in a study with the same inclusion criteria as the SHARP trial but, because of the confirmatory nature of the trial, with less than half the number of patients \[[@B5]\]. The OS in both arms of the Asia-Pacific study was shorter than that for the SHARP trial, i.e., 6.5 months in the sorafenib group and 4.5 months in the placebo group. Possible explanations for these absolute differences in survival between the two trials include a larger number of patients with extrahepatic spread in the Asia-Pacific study, with more advanced Eastern Cooperative Oncology Group (ECOG) performance status, the inclusion of patients with more than four tumor sites, and a larger number of patients with lung metastasis (50% in the Asia-Pacific trial, 21% in the SHARP trial). In addition, it cannot be ruled out that the Asian patients, mostly with Hepatitis B-associated HCC, in general show a more aggressive course of disease (and may well be detected at a later stage, as exemplified by the more advanced disease at inclusion into the Asia-Pacific trial). Nevertheless, the effect of sorafenib on OS was consistent between the two trials. Sorafenib also prolonged the time to progression (TTP), both in the SHARP trial (TTP: sorafenib 5.5 months versus placebo 2.8 months, p\<0.001) and in the Asia-Pacific trial (TTP: sorafenib 2.8 months versus placebo 1.4 months, p\<0.001).

The most common adverse events were diarrhea (39%) and hand-foot skin reaction (21%), followed by anorexia and alopecia with both 14% \[[@B4]\]. Nevertheless, most adverse events were of low grade (G1/2) and did not lead to discontinuation of the study drug. When looking at different subgroups of patients, it is important to know that sorafenib seems to work irrespective of the underlying disease etiology, any prior therapy received, or the pattern of vascular invasion or extrahepatic spread \[[@B12]\].

From the SHARP and the Asia-Pacific trials, because of the restrictive inclusion criteria, there is insufficient information about the effect of sorafenib in patients with more advanced liver disease (Child-Pugh B, Child-Pugh C) \[[@B13]\]. The first report on the survival outcome of patients with more advanced stage liver disease came from the real life Austrian cohort and showed that patients with Child B cirrhosis live about half as long as patients with Child A liver function (OS: Child A 11.3 months versus Child B 5.5 months). Well patients with Child C cirrhosis die very quickly despite sorafenib treatment (median OS 1.6 months) and they do not seem to be candidates for treatment with sorafenib \[[@B14]\]. These data were later confirmed by the large multinational phase IV observational study GIDEON, which included over 3000 patients with different degrees of liver function \[[@B15]\]. Unfortunately, no controlled data are available to indicate whether patients with Child B liver dysfunction are deriving a benefit from treatment with sorafenib, but at least one prospective randomized phase-III trial in Child B patients is currently ongoing to answer this question (BOOST, [www.clinicaltrials.gov](http://www.clinicaltrials.gov), NCT01405573).

In the absence of a prospective trial to answer this question, we looked at prognostic factors in the Austrian cohort to predict survival in patients with advanced-stage HCC and different degrees of liver dysfunction during sorafenib treatment. We were able to identify elevated aspartate aminotransferase (AST) levels as a very reliable and sensitive prognostic factor for patients undergoing sorafenib treatment \[[@B16]\]. Looking at the whole cohort with different degrees of liver dysfunction, AST \<100 IU/L indicated a median OS of 10.2 months, whereas AST ≥100 IU/L was associated with a median OS of only 2.7 months. The AST level remained a very strong and significant prognostic factor not only in Child A patients but also in the subgroup of Child B patients with advanced-stage HCC; in the latter group, the same cut-off for AST of 100 IU/L was able to distinguish between patients with a median OS of 6.5 months versus a median OS of 2.1 months. Thus, the AST level, which also is a very strong predictor for survival in intermediate-stage patients undergoing transarterial chemoembolization \[[@B17]\], is a simple, non-invasive, and accurate marker to rationally guide the use of sorafenib, particularly in resource-limited settings. Despite these data and the official recommendations in various international guidelines, foremost the EASL clinical practice guidelines \[[@B7]\], sorafenib is by far not the most commonly used treatment for patients with advanced-stage liver disease. As exemplified by the European data of the large worldwide observational BRIDGE study, sorafenib treatment accounts for only about 10% of the treatments used for advanced-stage HCC patients in Europe \[[@B18]\]. Most patients with advanced stage liver disease are not receiving medical treatment but all kinds of surgical to interventional treatments even in advanced stage HCC. If medical therapy is used in this patients, than at least in Europe and North America sorafenib is prescribed in over 90% of the patients, while in Asia only slightly more than 50% of patients are treated with sorafenib. A considerable number of patients receive other medical treatments, most of them chemotherapy-based \[[@B19]\].

First-Line Treatments for HCC beyond Sorafenib {#sec1_3}
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The success of the TKI sorafenib for the treatment of HCC stimulated initiation of several clinical trials with similar drugs for this indication in prospective phase-III trials. The first to be completed was the first-line trial of sunitinib versus sorafenib, a randomized trial of 1074 patients comparing sunitinib 37.5 mg/day versus sorafenib in standard dose (800 mg/day). Since this trial was preceded by two phase-II trials with mixed results, it was not surprising to find that sunitinib was significantly worse in terms of OS than sorafenib was (median OS 7.9 versus 10.2 months, p=0.014) \[[@B20]\]. This difference was particularly pronounced in hepatitis-C-positive patients (median OS: sunitinib 9.2 versus sorafenib 17.6 months). Since the progression-free survival and the TTP were similar in both groups, the difference in OS results was most likely caused by the significantly higher toxicity of sunitinib in patients with HCC.

The next drug to be tested in a phase-III trial against sorafenib was brivanib, a VEGF-receptor-, fibroblast growth factor receptor-blocking multikinase TKI \[[@B21]\]. Again, in a large multinational phase-III trial involving 1155 patients, brivanib was unable to demonstrate non-inferiority to sorafenib (median OS brivanib 9.5 versus sorafenib 9.9 months; HR 1.07, p=0.3116) \[[@B22]\]. Linifanib, a PDGF/VEGF-receptor TKI, also failed to show a survival advantage over sorafenib in a large phase-III trial (OS linifanib 9.1 versus sorafenib 9.1 months; HR=1.046) \[[@B23], [@B24]\].

Attempting to combine sorafenib with another targeted agent has not been successful so far: when sorafenib was combined with the epidermal growth factor receptor-inhibitor erlotinib in the SEARCH phase-III trial, the combination of sorafenib and erlotinib (median OS 9.5 months) was not significantly better than sorafenib monotherapy (median OS 8.5 months; HR 0.929; p=0.204) \[[@B25]\].

While still quite a few phase-III trials in the first-line setting for HCC are ongoing, testing drugs like Lenvatinib ([www.clinicaltrials.gov](http://www.clinicaltrials.gov); NCT01761266), a multikinase TKI inhibiting VEGFR2 and 3 \[[@B26]\], drug treatment for advanced stage HCC beyond sorafenib does not seem to be an easy target for drug development. Currently, a major search for informative biomarkers is taking place that should allow a more targeted approach in subgroups of patients with specific molecular profiles. That approach would allow to extend the survival of those patients by selective drug targeting beyond the survival achievable with sorafenib. Even though HCC is a heterogeneous tumor with different grades of differentiation within a single lesion and often considerable necrotic areas within a given tumor, this approach currently seems to be the most rational and promising \[[@B27]\]. It remains to be seen whether simple immunohistochemistry with a few markers or complex genetic analysis with microarray technology will yield informative results for drug development. But success without a rational approach seems unlikely.

Second-Line Therapy for HCC {#sec1_4}
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Despite the significant improvement in OS with sorafenib, it only delays progression of the tumor (median TTP 5.5 months versus 2.8 months with placebo) \[[@B4]\]. This means that there is a great need for an active second-line treatment after progression with sorafenib. One obvious approach would be to continue sorafenib despite progression, but no definitive data are currently available as to whether this approach would be of any use. In particular, in the SHARP trial it was left to the discretion of the investigator what to do after progression. Some investigators continued sorafenib while others discontinued it. No conclusion can therefore be drawn from the SHARP study regarding what to do after progression. Another approach that works in kidney cancer would be to increase the dose of sorafenib with progression, but the only study available so far has too few patients enrolled for any relevant conclusion to be drawn and does not show a difference in median progression-free survival, which might not have much relevance for median OS \[[@B28]\]. Another line of attack taken by several pharmaceutical companies was to test targeted agents with slightly different molecular profiles than sorafenib. The first second-line phase-III trial to be reported was the BRISKPS (brivanib-post sorafenib) trial, which was not able to show any improvement in median OS with brivanib compared to best supportive care plus placebo (median OS: brivanib 9.4 months versus placebo 8.2 months; HR 0.89, p=0.3307) \[[@B29]\]. The results of this trial were surprising and disappointing at the same time, but even when looking at detailed subgroup analyses, brivanib did not seem to offer a survival benefit in any of the subgroups analyzed: neither according to geographic region, nor to etiology of liver disease, nor to ECOG performance status, nor to tumor distribution, nor to tumor size. The second phase-III trial in a second-line setting to be reported was the EVOLVE-1 trial. Here, everolimus, an mTOR inhibitor, was tested at a daily dose of 7.5 mg versus placebo but was able to show only a modest benefit in median OS (everolimus 7.6 months versus placebo 7.3 months; HR 1.05, p=0.675) \[[@B30]\]. In this study, there was no benefit in the median TTP, or in the overall population, or in any of the pre-stratified subgroups. Only the disease control rate was significantly better in the everolimus group, which has little meaning for the overall evaluation of the results. The ongoing REACH phase-III trial is testing the monoclonal anti-VEGFR2 antibody ramucirumab in the second-line setting for HCC after sorafenib failure. Judging from the first-line phase-II data, this antibody, which is used intravenously at a dose of 8 mg/kg every 2 weeks, could have significant effects on overall survival of patients with advanced-stage HCC \[[@B31]\].

Another oral multikinase inhibitor, which is currently in phase-III development, is regorafenib, a raf-, VEGF-, PDGF-, Tie2-inhibitor \[[@B32]\]. Because regorafenib has a similar but more extended target range and a more potent action compared to sorafenib, this drug is tested only in patients with progression under sorafenib but not in those with intolerance to sorafenib.

A current focus of interest for HCC drug development is the c-met inhibitor tivantinib. In early gene array studies, it was demonstrated that elevated expression of c-met was associated with poor outcome and short overall survival in patients with liver cancer \[[@B33]\]. In a highly publicized phase-II trial, tivantinib was able to significantly improve overall survival in patients with high c-met expression in the tumor tissue, whereas it had no effect on median OS in patients with low expression of c-met \[[@B34]\]. In the two currently ongoing phase-III trials ([www.clinicaltrials.gov](http://www.clinicaltrials.gov), NCT01755767 for the European/US trial, NCT02029157 for the Japanese trial), tivantinib is being tested in patients with sorafenib failure against best supportive care and placebo. Despite initial problems with severe neutropenia in the European/US trial due to a change in the drug formulation used in the phase-III as compared to the phase-II trial, this study is currently ongoing and is actively recruiting patients.

Besides tivantinib, other c-met inhibitors are undergoing clinical testing, e.g., cabozantinib \[[@B35]\] in a second-line phase-III trial ([www.clinicaltrials.gov](http://www.clinicaltrials.gov); NCT01908426) and Inc-280 in a first-line phase-II trial ([www.clinicaltrials.gov](http://www.clinicaltrials.gov); NCT01737827). A similarly targeted approach is being taken with the MEK-inhibitor refametinib \[[@B36]\] in Ras-mutated HCC in two single-arm phase-II trials ([www.clinicaltrials.gov](http://www.clinicaltrials.gov); first line combined with sorafenib: NCT01915602, and second line versus placebo: NCT01915589). Refametinib is a very interesting compound, albeit with potential application to only a small subgroup of HCC-patients.

Future Prospects {#sec1_5}
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Even though many drug companies are taking a more cautious approach after the failure of several phase-III trials for first- and even second-line treatment of advanced-stage and even earlier stage liver cancer, there is still great hope for a further step forward in the medical treatment of HCC \[[@B37]\]. The more targeted, tumor biology-driven approaches now being taken, together with careful clinical trial design \[[@B38]\], will offer a greater chance for success than in the past. Nevertheless, much more basic research on HCC tumor biology is needed in order to be successful in a third and fourth wave of drug development for a difficult to treat tumor such as liver cancer, even in patients with well-preserved liver function.
